Table 2

The profiles of immunological outcomes of patients by achievement of none, one or both of the two target immunological markers (CD4 ≥500, CD4:CD8 ratio ≥0.8) before the end of a 4-year observation period*

NumberMedian peak or highest CD4 count (/μL) (IQR)Median months to CD4 target (IQR)Median peak or highest CD4:CD8 ratio (IQR)Median months to target CD4:CD8 ratio (IQR)
CD4 ≥500/μL and CD4:CD8 ratio ≥0.8105741 (618–876)20.63 (12.6–30.53)0.98 (0.86–1.2)28.90 (14.43–42.95)
Concurrent achievement of both targets15694 (569–1182)20.27 (13.07–28.17)1.05 (0.9–1.49)20.27 (13.07–28.17)
CD4 target before ratio target57788 (660–921)15.13 (8.7–22.88)0.89 (0.83–0.99)39.23 (30.78–45.98)
Ratio target before CD4 target33650 (547–764)31.13 (22.3–39.4)1.17 (1.02–1.56)14.40 (8.68–24.08)
CD4 ≥500/μL only205622 (552–723)29.10 (17.43–38.37)0.59 (0.49–0.69)
Ratio ≥0.8 only32431 (369–475)1.05 (0.89–1.17)29.32 (18.48–40.33)
CD4 target then changed to ratio target4588 (519–660)20.02 (12.23–35.36)0.86 (0.81–0.95)36.83 (20.68–49.72)
Ratio target then changed to CD4 target4583 (521–636)29.68 (20.52–40.38)0.87 (0.86–1.01)13.87 (5.48–25.45)
Failure to achieve both targets365362 (253–432)0.43 (0.31–0.55)
  • *Equivalent to a maximum of <52 months with the inclusion of a 3-month buffer period.